News | August 02, 2021
Ajanta Pharma aims to file 10-12 ANDAs per annum
India business is growing as per projections; whereas US business will bounce back soon.
India business is growing as per projections; whereas US business will bounce back soon.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The end user can validate the authenticity of the product by scanning the digital code with the help of a smartphone letting the end user know it is safe to use
Under the PMBJP, all the districts of the country are covered and ensure easy reach of affordable medicine to the people in every nook and corner of the country
Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
The company is doubling its chemistry research capacity that should commission by Q2'FY22
Aurobindo has one of the most enduring generics ecosystems among peers
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
Adjusted PAT declined 18.8% YoY
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
Subscribe To Our Newsletter & Stay Updated
